tirzepatide safety vs semaglutide safety vs. Tirzepatide: Understanding Which is Best for You Comparison of Tirzepatide versus Semaglutide

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound) in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, as an adjunct to diet and physical activity

Medications from pharmacies that follow FDA regulations are safer, even if they cost more

In this study, patients were randomized to receive subcutaneous semaglutide (0.5 mg or 1.0 mg) once a week or placebo

Other Considerations Questions sometimes arise about kidney stones Mounjaro and other kidney related concerns

Am J Gastroenterol 2024;119(10S):S587S588.Article 22

Take small sips instead of gulping down your drinks